Capital One served as administrative agent and lead arranger on a $350 million senior credit facility for Covis Pharma. The facility includes a $25 million revolver and a $325 million term loan.
Covis used the funding to acquire the worldwide rights for medicines Alvesco, Omnaris and Zetonna.
“This is an exciting milestone for Covis, as we continue to execute on our strategy of building a global respiratory and allergy franchise,” said Michael Porter, Covis Pharma CEO.
“Thanks to their track record and expertise in the pharmaceutical industry, Capital One was able to provide us with the required certainty of execution to help complete this transformational transaction,” said Alexander Mironov, Covis executive vice president of Business Development and M&A.
“Due to our knowledge of the space and the working relationship that we have developed over time with the Covis management team, we were able to exceed the company’s expectations in a relatively compressed time frame,” said Jason Cohen, managing director, Capital One Healthcare.
Founded in 2011 by Cerberus Capital and Management and based in Zug, Switzerland, Covis Pharma is a specialty pharmaceutical company that focuses on acquiring high-quality, established branded pharmaceuticals and improving performance through optimizing positioning and supply chains supported by targeted product development initiatives.
